T cell receptor gamma joining P1Genealiases: JP1 · TCRGJP1
Q-omics provides the consensus-scored TRGJP1 profile across patient tissues and cancer cell-line models. TRGJP1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TRGJP1 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, TRGJP1 RNA expression shows 8,978 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, LUAD, and THYM as cancer lineages where TRGJP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRGJP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRGJP1 survival associations across molecular data types. TRGJP1 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRGJP1 RNA expression–survival associations across cancer types. High TRGJP1 expression shows unfavorable associations in KIRP, ACC, LUSC, CHOL and DLBC, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TRGJP1 RNA expression.
This table summarizes TRGJP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRGJP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRGJP1 shows lower tumor expression in LUAD, LUSC and COAD and higher tumor expression in KIRC. The LUAD box plot shows higher TRGJP1 RNA expression in normal versus tumor tissue (log2 FC = −0.858, t-test p < 0.001).
This table shows molecular features associated with TRGJP1 in patient tissues and cancer cell lines. In patient samples, TRGJP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
